Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;16(3):199-211.
doi: 10.1007/s40272-014-0065-5.

The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy

Affiliations
Review

The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy

Svetlana Madjunkova et al. Paediatr Drugs. 2014 Jun.

Abstract

Nausea and vomiting of pregnancy (NVP) affects up to 85 % of all pregnancies. Effective treatment can greatly improve a woman's quality of life, reduce the risk for maternal and fetal complications, and reduce healthcare costs. Unfortunately, many women receive either no pharmacological treatment or are recommended therapies for which fetal safety and efficacy have not been established. First-line treatment of NVP, as recommended by several leading healthcare and professional organizations, is the combination of doxylamine and pyridoxine. This combination, formulated as a 10 mg/10 mg delayed-release tablet, was approved by the US Food and Drug Administration (FDA) for the treatment of NVP in April 2013 under the brand name Diclegis(®), and has been on the Canadian market since 1979, currently under the brand name Diclectin(®). The efficacy of Diclegis(®)/Diclectin(®) has been demonstrated in several clinical trials, and, more importantly, studies on more than 200,000 women exposed to doxylamine and pyridoxine in the first trimester of pregnancy have demonstrated no increased fetal risk for congenital malformations and other adverse pregnancy outcomes. The present review aims to present the scientific evidence on the effectiveness and fetal safety of Diclegis(®)/Diclectin(®) for the treatment of NVP to justify its use as first-line treatment for NVP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structure of Diclegis®/Diclectin® [10 mg doxylamine succinate/10 mg pyridoxine hydrochloride (HCl)]. a Doxylamine succinate is classified as an antihistamine. The chemical name for doxylamine succinate is ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-butanedioate (1:1) 2-[α-[2-(dimethylamino)ethoxy]-α-methylbenzyl] pyridine succinate (1:1). The empirical formula is C17H22N2O · C4H6O4 and the molecular mass is 388.46 g/mol. It is very soluble in water and alcohol, readily soluble in chloroform, and slightly soluble in ether and benzene. b Pyridoxine HCl is vitamin B6. Its chemical name is 5-hydroxy-6-methyl-3,4-pyridine dimethanol hydrochloride. The empirical formula C8H11NO3 · HCl and molecular mass is 205.64 g/mol. Pyridoxine HCl is readily soluble in water, slightly soluble in alcohol, and insoluble in ether

Similar articles

Cited by

References

    1. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol. 2000;182(4):931–7. - PubMed
    1. Clark SM, Costantine MM, Hankins GD. Review of NVP and HG and early pharmacotherapeutic intervention. Obstet Gynecol Int. 2012;252676(10):24. - PMC - PubMed
    1. APGO. Nausea and vomiting of pregnancy. APGO Educational series on women’s health issues. Boston: Jespersen & Associates, LLC; 2013.
    1. Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008;35(3):401–417. doi: 10.1016/j.ogc.2008.04.002. - DOI - PubMed
    1. Czeizel AE, Dudas I, Fritz G, Tecsoi A, Hanck A, Kunovits G. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet. 1992;251(4):181–185. doi: 10.1007/BF02718384. - DOI - PubMed

Publication types